Back to top
more

Immunovant (IMVT)

(Delayed Data from NSDQ)

$28.80 USD

28.80
667,914

+0.19 (0.66%)

Updated Apr 24, 2024 04:00 PM ET

After-Market: $28.82 +0.02 (0.07%) 4:32 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth C Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 31% (78 out of 252)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Here's Why You Should Add Immunovant (IMVT) to Your Portfolio

Immunovant's (IMVT) late-stage studies evaluating its lead candidate, batoclimab, for various autoimmune indications are progressing well. Several data readouts are expected in 2024 and 2025.

What Makes Immunovant (IMVT) a New Buy Stock

Immunovant (IMVT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Why Argenx's (ARGX) Stock Price Moved Up 11% on Thursday

Argenx (ARGX) surges after a Japanese rival posted disappointing results from a late-stage study on its investigational drug for generalized myasthenia gravis.

Why Is Immunovant, Inc. (IMVT) Down 14.7% Since Last Earnings Report?

Immunovant, Inc. (IMVT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Here's Why Immunovant, Inc. (IMVT) is Poised for a Turnaround After Losing -8.02% in 4 Weeks

The heavy selling pressure might have exhausted for Immunovant, Inc. (IMVT) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Immunovant (IMVT) Up 3% as Q3 Earnings Top, Pipeline in Focus

Immunovant (IMVT) gains 3% on encouraging fiscal third-quarter 2024 results. Pipeline development is on track, with several data readouts scheduled from both batoclimab and IMVT-1402 programs.

Immunovant (IMVT) Up on Upbeat Initial Batoclimab GD Study Data

Immunovant (IMVT) announces positive initial data from the mid-stage study of batoclimab in patients with Graves' disease. The stock gains 12% in the after-market hours, following the news.

Is SPDR S&P Biotech ETF (XBI) a Strong ETF Right Now?

Smart Beta ETF report for XBI

Immunovant (IMVT) Up on Positive Initial IMVT-1402 MAD Study Data

Immunovant (IMVT) posts encouraging initial results from the 600 mg MAD cohort of its early-stage study on IMVT-1402. Stock rises.

Should You Invest in the SPDR S&P Biotech ETF (XBI)?

Sector ETF report for XBI

Immunovant (IMVT) Q2 Earnings Top Estimates, Pipeline in Focus

Immunovant (IMVT) reports better-than-expected fiscal second-quarter 2023 results. Pipeline development is on track, with several data readouts scheduled from both batoclimab and IMVT-1402 programs.

Biotech Stock Roundup: ICPT Up on Buyout Deal, IMVT & PLRX Gain on Study Data

Acquisition news from Intercept (ICPT) and study updates from Immunovant (IMVT) are in focus in the biotech sector.

Immunovant (IMVT) Soars on Upbeat Initial IMVT-1402 Study Data

Immunovant (IMVT) announces encouraging initial results from its early-stage study of IMVT-1402. The stock of the company rallies 97%.

Immunovant (IMVT) Q1 Loss Wider Y/Y, Pipeline in Focus

Immunovant's (IMVT) reports wider-than-expected loss for fiscal first-quarter 2023. IMVT is on track with the pipeline developments.

Immunovant, Inc. (IMVT) Down 10.6% Since Last Earnings Report: Can It Rebound?

Immunovant, Inc. (IMVT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Is IQ Chaikin U.S. Small Cap ETF (CSML) a Strong ETF Right Now?

Smart Beta ETF report for CSML

Immunovant (IMVT) Q4 Earnings Top Estimates, Pipeline in Focus

Immunovant (IMVT) reports narrower-than-expected results in fourth-quarter fiscal 2023. Pipeline development is on track. Stock surges 12% on Monday.

Is IQ Chaikin U.S. Small Cap ETF (CSML) a Strong ETF Right Now?

Smart Beta ETF report for CSML

Should IQ Chaikin U.S. Small Cap ETF (CSML) Be on Your Investing Radar?

Style Box ETF report for CSML

Is IQ Chaikin U.S. Small Cap ETF (CSML) a Strong ETF Right Now?

Smart Beta ETF report for CSML

Should IQ Chaikin U.S. Small Cap ETF (CSML) Be on Your Investing Radar?

Style Box ETF report for CSML

The Zacks Analyst Blog Highlights Merck, Vertex Pharmaceuticals, Immunocore Holdings and Immunovant

Merck, Vertex Pharmaceuticals, Immunocore Holdings and Immunovant are part of the Zacks top Analyst Blog.

Kinjel Shah headshot

4 Drug Stocks Up More Than 40% YTD With Room to Grow in 2023

Here are four drug companies, MRK, VRTX, IMCR and IMVT, that are up 40% or more in 2022 so far and still have room for growth in 2023.

Are Medical Stocks Lagging Immunovant (IMVT) This Year?

Here is how Immunovant, Inc. (IMVT) and McKesson (MCK) have performed compared to their sector so far this year.

Are Medical Stocks Lagging BioVie (BIVI) This Year?

Here is how BioVie Inc. (BIVI) and Immunovant, Inc. (IMVT) have performed compared to their sector so far this year.